Products from BPS Bioscience require a minimum order value above 400€
Application: 1. Study the mechanism of viral transduction
2. Screening for neutralizing antibodies that inhibit the interaction between ACE2 and the Spike protein of SARS-CoV-2 variants.
3. Identify variant-specific antibodies recognizing the different Spike mutations.
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Numerous SARS-CoV-2 variants have been identified so far. These variants contain a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than the original strain.BPS Bioscience has launched a series of Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter). The Spike (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike Variant (see below for mutation details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus Pack (Luciferase Reporter) contains a collection of 12 Spike variants (SARS-CoV-2) Pseudotyped lentivirus (Luc reporter). It is a great tool to screen for variant-specific antibodies or to test the binding or efficacy of drug candidates against the different Spike variants. The Spike (SARS-CoV-2) pseudotyped lentiviruses can be used to measure the activity of neutralizing antibody against SARS-CoV-2 infection in a Biosafety Level 2 facility.
Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS.Thaw Medium 1 (BPS Bioscience, #60187): MEM medium (Hyclone, #SH30024.01) supplemented with 10% FBS, 1% non-essential amino acids (Hyclone, #SH30238.01), 1 mM Na pyruvate, 1% Penicillin/Streptomycin (Hyclone, #SV30010.01).
Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C.
Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.Biosafety: of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Biosafety Level: BSL-2
Deutsch
English
